April 08, 2019
In our January Blog Post related to the January 2019 USPTO Subject Matter Eligibility Guidance (“the Guidance”), and our subsequent Blog Post in February , we noted that it was unclear how the courts will view issued personalized medicine claims examined under the Guidance, as it appeared that the USPTO may want to push the courts to reexamine the… Read more »
February 11, 2019
In our January 22, 2019 Blog Post related to the January 2019 USPTO Subject Matter Eligibility Guidance (“the Guidance”), we noted that in Prong Two of Step 2A of the Guidance, an Examiner is tasked with evaluating “whether the claim as a whole integrates the recited judicial exception into a practical application of the exception.”1 More importantly, we… Read more »
January 22, 2019
The USPTO’s recently revised guidance for determining subject matter eligibility under 35 U.S.C. § 101 (“the Guidance”),1 provides some clarity to Examiners and Applicants as to what constitutes an “abstract idea.” While the Guidance identifies several abstract ideas that fall within the scope of a “Judicial Exception” during Prong One of the Alice/Mayo test (Step 2A of the… Read more »